Raphael Borie | Gene Regulation Epigenetics | Best Researcher Award

Posted on by sciencefather

Prof. Dr. Raphael Borie | Gene Regulation Epigenetics | Best Researcher Award

Prof. Dr. Raphael Borie, APHP, France

Dr. Raphaël Borie, born on August 15, 1977, in Paris, France, is a leading expert in pulmonology and genetic respiratory diseases. Currently a University Professor Hospital Practitioner at Bichat Hospital (Paris Cité University), he has consistently contributed to the advancement of respiratory medicine, particularly in the field of interstitial lung diseases (ILDs). His clinical insight, combined with a strong research portfolio, has positioned him as a prominent figure within the OrphaLung network. A dedicated family man with two children, Dr. Borie is widely respected for his integrity, leadership, and commitment to collaborative medicine. His career reflects a unique blend of academic excellence and impactful translational research, bridging the gap between genomics and clinical care in ILD. He is a registered member of the French Medical Council (Ordre des Médecins No. 75/71138), and his research has influenced European clinical guidelines and improved the understanding of rare genetic pulmonary conditions.

Publication Profile: 

Scopus

✅ Strengths for the Award:

  1. Robust Academic Background:
    Dr. Borie holds a PhD in Genetics, Master’s in Physiology, and HDR (habilitation to supervise doctoral research), which underlines his scientific credibility and ability to lead independent research.

  2. Clinical-Research Integration:
    As a University Professor and Hospital Practitioner, he merges frontline patient care with cutting-edge genetic and respiratory disease research.

  3. High Publication Impact:
    With 283 PubMed-indexed articles and an H-index of 60, Dr. Borie’s work demonstrates strong citation influence, indicating widespread recognition and utility in the scientific community.

  4. International Leadership:
    Active in multinational collaborations (e.g., OrphaLung, ERS), he has co-authored major position statements and clinical trials, influencing European respiratory care guidelines.

  5. Innovation in Rare Diseases:
    A recognized expert in familial interstitial lung disease and telomere disorders, his work has led to earlier diagnosis and targeted therapies—critical in fields where few experts exist.

  6. Recognition and Funding:
    He has secured prestigious mobility grants (ERS, Respirology Teachers College)—a marker of trust in his scientific mission and innovation.

🔍 Areas for Improvement:

  • Wider Public Health Translation: While Dr. Borie’s genomic research is exceptional, expanding into real-world health policy implementation could enhance systemic impact.

  • Patient Engagement & Advocacy: Developing patient-oriented tools or registries (e.g., digital apps or platforms for familial lung diseases) may broaden his outreach beyond academia and clinics.

  • Broader Visibility: Although highly cited in professional circles, participation in international keynote talks, editorial leadership, or mainstream health media could elevate his public and professional visibility.

🎓 Education:

Dr. Borie has pursued an extensive and rigorous academic path focused on respiratory and genetic medicine. He obtained his medical degree with specialization in Allergology and Immunopathology in 2006. A year earlier, in 2005, he earned a Master’s degree in Biology and Physiology of Circulation and Respiration. Demonstrating deep interest in genetics, he completed a PhD in Genetics in 2017, contributing significantly to our understanding of genetic underpinnings in pulmonary fibrosis. In 2019, Dr. Borie achieved the prestigious Habilitation à Diriger des Recherches (HDR) from the University of Paris 7, enabling him to supervise doctoral research. His academic background illustrates a powerful integration of clinical expertise and molecular research—providing him with the tools to lead innovative research projects at the intersection of genomics and pulmonology.

🩺 Experience:

Dr. Raphaël Borie has over 15 years of experience in respiratory medicine. From July 2011 to August 2020, he served as a Hospital Practitioner in the Pneumology Department at Bichat Hospital under Professors Aubier and Crestani. Since September 2020, he has been a University Professor Hospital Practitioner in the same department, affiliated with Paris Cité University. He has contributed to patient care, education of medical students and residents, and cutting-edge research. As part of the OrphaLung network, he plays a critical role in advancing diagnostic tools and treatment approaches for rare lung diseases. He is recognized for his collaborative leadership and interdisciplinary contributions across genetics, immunology, and pulmonology. His international collaborations and authorship of over 280 PubMed-indexed publications demonstrate his ongoing commitment to improving patient outcomes through translational research.

🏆 Awards and Honors:

Dr. Borie’s research excellence has been recognized through several prestigious awards and scholarships. In 2017, he received the European Respiratory Society (ERS) Mobility Grant for his work on Identification of Preclinical Markers of Pulmonary Fibrosis, supporting international collaboration and advanced training. The same year, he was also honored with the Respirology Teachers College Mobility Grant, reinforcing his pioneering research on early detection of fibrotic lung disease. His selection for these awards highlights both scientific innovation and dedication to knowledge exchange. His leadership in multi-center studies and involvement in ERS guideline statements further reflect his status as a thought leader in interstitial lung disease. These honors are a testament to his influence in shaping the future of pulmonary genetics and translational respiratory medicine.

🔬 Research Focus:

Dr. Raphaël Borie’s research centers on familial and genetic interstitial lung diseases, particularly the molecular mechanisms behind pulmonary fibrosis, telomere biology, surfactant-related gene variants, and early detection strategies. He works extensively on identifying genetic risk variants (e.g., MUC5B, DSP) and their implications in idiopathic pulmonary fibrosis. Through his participation in the OrphaLung network, he supports genomic screening for hereditary lung disorders and contributes to developing European guidelines. His work bridges genomic medicine and clinical pulmonology, aiming for earlier diagnosis and personalized treatment approaches. He has led and co-authored critical studies on RTEL1 mutations, telomerase complex defects, and familial ILD phenotypes, helping clinicians globally understand the heterogeneity and systemic implications of genetic lung disorders. His collaborative international research ensures his findings are applied in practice to optimize long-term patient care.

📚Publications Top Notes:

  • 🧬 High risk of lung cancer in surfactant-related gene variant carriers – Eur Respir J, 2024

  • 📄 European Respiratory Society Statement on Familial Pulmonary Fibrosis – Eur Respir J, 2022

  • 🧪 Colocalization of Gene Expression and DNA Methylation with Genetic Risk Variants – Am J Respir Crit Care Med, 2022

  • 🧬 RTEL1 mutations and their phenotypic variability – Eur Respir J, 2019

  • 💊 Safety and efficacy of pirfenidone in telomerase mutation carriers – Eur Respir J, 2018

  • 🌐 Diagnosis and follow-up of familial ILD: International survey – BMC Pulmonary Med, 2025

  • 🧬 New 2023 ACR/EULAR APS criteria performance in young patients – Letter, 2025

  • 🫁 A non-resolving cough: a case of familial pulmonary fibrosis – Breathe, 2025

  • 🧬 PFMG2025: Genomic medicine in French healthcare system – Review, 2025

  • 💊 Efficacy of CFTR modulators in ABCA3-deficiency ILD – Open Access, 2025

  • 🧠 Neurological manifestations in VEXAS syndrome – Journal of Neurology, 2025

  • 💉 Real-life use of PEXIVAS reduced-dose regimen in vasculitis – Ann Rheum Dis, 2025

  • 🧫 Recurrent respiratory papillomatosis with lung involvement – Eur Respir J, 2025

  • 🔍 RA-ILD: genetics to clinical overview – Review, 2025

  • 👶 Childhood ILD survivors in adulthood: European study – Eur Respir J, 2025

🧾 Conclusion:

Dr. Raphaël Borie exemplifies the ideal candidate for the Best Researcher Award. His excellence spans across clinical expertise, academic distinction, and international research leadership, especially in genetic and familial interstitial lung diseases—a field with enormous unmet need. His consistent scholarly output, impactful collaborations, and patient-focused studies highlight a unique blend of depth and innovation. While further expansion into public health frameworks and patient engagement tools would be valuable, his profile already reflects a world-class researcher with transformative contributions to pulmonary medicine.

Yang Gao | Cell Differentiation Processes | Best Researcher Award

Posted on by sciencefather

Prof. Dr. Yang Gao | Cell Differentiation Processes | Best Researcher Award

Prof. Dr. Yang Gao , The Sixth Affiliated Hospital of Harbin Medical University , China

Professor Yang Gao is the Chief Physician and Director of the Critical Care Medicine Department at The Sixth Affiliated Hospital of Harbin Medical University, China. He is a respected academic and clinical expert in critical care, serving also as a Doctoral Supervisor. With over two decades of frontline medical experience, Professor Gao has led nine major research projects and published 33 SCI-indexed papers, amassing a citation index of 313 and an overall impact factor of 94.493. He holds prominent roles in national and provincial academic societies, contributing to innovations in sepsis, AKI, and renal replacement therapy (RRT). His dedication to clinical advancement is matched by his commitment to medical education and research. Recognized for his pioneering work in critical care medicine, he has received patents and published multiple medical textbooks. His leadership, extensive research contributions, and continued impact on critical care practices make him a strong candidate for the Best Researcher Award.

Publication Profile:

Scopus

✅ Strengths for the Award:

  1. Extensive Clinical & Research Expertise: With over two decades in frontline critical care, Professor Gao combines clinical acumen with deep research insight, particularly in sepsis-associated acute kidney injury (AKI) and continuous renal replacement therapy (RRT).

  2. High-Impact Research Output: He has authored 33 SCI-indexed publications with a cumulative impact factor of 94.493 and over 313 citations, reflecting global recognition and academic influence.

  3. Research Leadership: Professor Gao has successfully led 9 major research projects, funded at national and provincial levels, demonstrating his capability in resource management, innovation, and scientific leadership.

  4. Academic Contributions: His dual role as a doctoral supervisor and textbook author, along with a granted utility model patent, showcases a broad contribution to both research and education.

  5. Professional Recognition: Active in numerous national societies and editorial boards, he maintains a strong presence in shaping critical care medicine in China.

🔍 Areas for Improvement:

  • International Collaboration: While his national involvement is robust, fostering more international research partnerships would further expand the global relevance of his work.

  • Industry Engagement: Engagement with biotechnology or medical device industries could enhance translational applications of his findings in clinical settings.

🎓 Education:

Professor Yang Gao obtained his medical degree and advanced postgraduate training from institutions affiliated with Harbin Medical University, one of China’s leading medical schools. His rigorous academic journey included specialized training in critical care medicine, advanced life support technologies, and clinical research methodology. During his doctoral studies, he focused on critical illness mechanisms, with an emphasis on sepsis-associated acute kidney injury (AKI). He has consistently updated his expertise through postdoctoral fellowships and high-level academic forums. Further professional development was supported by the Heilongjiang Province Postdoctoral Start-up Fund, enhancing his academic and research foundation. Professor Gao’s medical education has equipped him with both theoretical knowledge and practical competence to lead complex multidisciplinary care units and mentor future medical scientists. His dual role as a clinical expert and academic leader reflects a strong commitment to translational medicine and healthcare innovation in China.

🏥 Experience:

With over 20 years of hands-on clinical experience, Professor Yang Gao has emerged as a leader in critical care medicine in China. Since 2003, he has been managing critically ill patients, mastering life-saving interventions such as non-invasive/invasive ventilation, blood purification, and continuous renal replacement therapy (CRRT). He is the Director of the Critical Care Medicine Department at The Sixth Affiliated Hospital of Harbin Medical University and holds teaching and supervisory roles for doctoral students. His experience spans both frontline medical services and academic research, with a portfolio that includes 33 SCI publications, textbook authorship, and national-level project leadership. In addition to clinical work, he contributes to national guidelines and policy-making through roles in multiple medical societies and editorial boards. Recognized for both his clinical excellence and scientific insight, Professor Gao has been instrumental in improving patient care outcomes and advancing the understanding of critical care physiology.

🔬 Research Focus:

Professor Yang Gao’s research is concentrated on the pathophysiology and treatment of sepsis-associated acute kidney injury (AKI) and the optimal application of continuous renal replacement therapy (CRRT). He has led and collaborated on key national and provincial projects, investigating biomarkers, timing of intervention, and therapeutic mechanisms in critically ill patients. His innovative work includes molecular-level studies on sepsis progression and clinical trials to determine best practices in critical care. He is also exploring analgesia and sedation protocols in ICU settings, as part of national key research programs. His published SCI research, with an impressive cumulative impact factor nearing 95, reflects his dedication to translating science into improved patient care. Through systemic analysis and advanced diagnostic models, Professor Gao is developing new frameworks for early identification of organ dysfunction, particularly kidney injury, in intensive care settings. His research continues to influence treatment protocols and critical care education across China.

📚 Publications Top Notes:

  1. 🧪 Magnetic properties and protective activity on burn disease by regulating mutated fibroblasts – J. Solid State Chem (2021)

  2. 🧫 Role of IL-10 and TNF-α in Sepsis-Induced AKI – Front. Immunol

  3. 🩺 Timing of CRRT in Septic Shock Patients with AKI – Crit Care Med

  4. 🔍 Identification of Biomarkers for Sepsis Progression in ICU – J Intensive Care

  5. 🧠 Neurological Outcomes in ICU Patients Receiving Sedation – Brain Res

  6. 🦠 MicroRNA Profiling in Sepsis-Induced Kidney Damage – Mol Med Rep

  7. 🧬 Effects of Early CRRT on Inflammatory Mediators – Cytokine

  8. 🧴 Pharmacokinetics of Antibiotics in CRRT Patients – Ther Drug Monit

  9. 🧍‍♂️ Prognostic Value of Serum NGAL in AKI Patients – Am J Nephrol

  10. 💉 Comparison of Hemoperfusion and Hemodialysis in Toxin Clearance – Blood Purif

🧾 Conclusion:

Professor Yang Gao stands out as a pioneering figure in critical care research, blending clinical innovation with scholarly rigor. His sustained contributions to understanding and treating sepsis and AKI, along with his strong academic leadership, make him eminently suitable for the Best Researcher Award. Recognizing his work will not only honor his achievements but also encourage continued excellence and international collaboration in life-saving medical science.

Arash Mokhtari | Medicinal Plant | Best Researcher Award

Posted on by sciencefather

Dr Arash  Mokhtari |  Medicinal Plant |  Best Researcher Award

Research fellow at  Agriculture Biotechnology Research Institute of Iran (ABRII), Iran

Arash Mokhtari is a distinguished Agricultural Biotechnologist with extensive expertise in plant tissue culture and advanced biotechnological methodologies. He earned his Ph.D. in Agricultural Biotechnology from the University of Tehran, Iran, where he achieved National Rank 2 with his research on elicitor-mediated gene expression in Valeriana officinalis. His Master’s degree, also from the University of Tehran, focused on the effect of plant growth regulators on somatic embryogenesis in wheat.

Profile:

Research Excellence

Innovative Research: Dr. Mokhtari’s research in plant tissue culture and agricultural biotechnology is cutting-edge. His work on the elicitor-mediated expression of genes in Valeriana officinalis, and optimization of bioactive compound extraction methods, demonstrates significant contributions to the field of agricultural biotechnology.

Publication Record: With numerous high-impact publications, including studies on efficient production and accumulation of valuable compounds, Dr. Mokhtari has a robust record of disseminating his research. His papers are published in reputable journals, reflecting the high quality and relevance of his work.

Leadership and Impact

Leadership Roles: As Head of the Plant Tissue Culture Laboratory and Advanced Research Greenhouses at the Agricultural Biotechnology Research Institute, Dr. Mokhtari has shown leadership in both research and practical applications. His role in managing teams and optimizing research protocols indicates his capability in driving significant advancements in his field.

National Recognition: Dr. Mokhtari has achieved high national rankings in his academic endeavors, including his Ph.D. and Master’s studies, which underscores his excellence and impact in the field of agricultural biotechnology.

Practical Applications

Agricultural Biotechnology: His research directly impacts agricultural practices by improving plant propagation techniques and enhancing crop yield efficiency. The practical applications of his work in plant tissue culture and genetic improvement are crucial for advancing agricultural productivity.

Professional Affiliations

Institutional Involvement: Dr. Mokhtari is affiliated with prestigious institutions, including the Agricultural Biotechnology Research Institute of Iran and the College of Agriculture and Natural Resources at the University of Tehran. His involvement with these organizations highlights his commitment to advancing agricultural biotechnology.

Conclusion

Dr. Arash Mokhtari’s extensive research contributions, leadership in advanced biotechnology research, and the practical implications of his work make him a highly suitable candidate for the Research for Best Researcher Award. His innovative approaches and significant achievements in plant biotechnology stand out as exemplary in his field.

Publication Top Notes:

  • “A highly efficient method for somatic embryogenesis of Kelussia odorotissima Mozaff., an endangered medicinal plant” in Plant Cell, Tissue and Organ Culture (PCTOC), 2017.
  • “Effect of plant growth regulators on direct shoot regeneration of wheat immature embryonic explants” in Journal of Agricultural Engineering and Biotechnology, 2013.
  • “Direct regeneration from leaves and nodes explants of Physalis peruviana L.” in International Journal of Farming and Allied Sciences, 2013.
  • “Rosmarinic acid and anthocyanin content improvement by foliar application of Fe and Zn fertilizer in Lemon balm (Melissa officinalis L.)” in International Journal of Advanced Biological and Biomedical Research, 2014.
  • “Plant regeneration through callus induction on medicinal herb Viola odorata – Role of plant growth regulators and explants” in Agriculture & Forestry, 2015.
  • “Callus induction and plant regeneration of Valeriana officinalis are affected by different leaf explants and various concentrations of plant growth regulators” in BioTechnologia, 2016.
  • “Rapid micropropagation of Cucumis sativus var. Dastgerdi (Iranian cultivar) by Node Culture Technique” in British Biotechnology Journal, 2014.
  • “Effect of Plant Growth Regulators on Seed Germination and Development of Protocorm and Seedling of Phalaenopsis amabilis (L.) Blume (Orchidaceae)” in Annual Research & Review in Biology, 2014.
  • “Engineering of secondary metabolites in tissue and cell culture of medicinal plants: an alternative to produce beneficial compounds using bioreactor technologies” in Crop Improvement: Sustainability Through Leading-Edge Technology, Springer Publications, 2017.
  • “Interactive effects of plant growth regulators and explants on direct shoot regeneration of Viola odorata” in BioTechnologia, 2016.
  • “Influence of plant growth regulators on in vitro culture and regeneration of Dracocephalum kotschyi” in International Journal of Agriculture Innovations and Research, 2014.